Bartlett & Co’s Acadia Pharmaceuticals ACAD Stock Holding History

Bartlett & Co’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-100	Closed	-$2K	–	1066
2022 Q3	$2K	Hold	100	–	–	﹤0.01%	1023
2022 Q2	$1K	Hold	100	–	–	﹤0.01%	1212
2022 Q1	$2K	Buy	+100	New	+$2.42K	﹤0.01%	985

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Bartlett & Co's ACAD Position: Q4 2022 in Review

Bartlett & Co sold out of Acadia Pharmaceuticals (ACAD) in Q4 2022, closing a stake of 100 shares — an estimated $2K sold.

Bartlett & Co first reported a position in ACAD in Q1 2022 and held it in 3 quarters. The position peaked at $2K in Q3 2022. 227 funds tracked by Wall St. Rank hold ACAD as of Q4 2022.

Bartlett & Co reported no remaining Acadia Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Bartlett & Co sold 100 Acadia Pharmaceuticals shares in Q4 2022, an estimated $2K.
Bartlett & Co first reported a position in Acadia Pharmaceuticals in Q1 2022 and held it in 3 quarters.
Bartlett & Co's Acadia Pharmaceuticals position peaked at $2K in Q3 2022.
227 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2022.

Based on Bartlett & Co's 13F filing for Q4 2022, filed 4 Jan 2023.